Table 1.

Patients charateristics and ENDOD1 expression of 50 prostate cancer patients

	Total no. cases (%)	ENDOD1 expression		P-value
		Low or none no. cases (%)	High no. cases (%)
All cases	50 (100)	22 (100)	28 (100)
Age
<69	24 (48)	10 (45.5)	14 (50)	0.749
≥69	26 (52)	12 (54.5)	14 (50)
PSA (ng/ml)
<10	25 (50)	8 (36.4)	17 (60.7)	0.196
10–20	12 (24)	6 (27.2)	6 (21.4)
>20	13(26)	8(36.4)	5(17.9)
Clinical T stage
cT1	37(74)	15(68.2)	22(78.6)	0.443
cT2	12(24)	6(27.3)	6(21.4)
cT3	1(2)	1(4.5)	0(0)
Biopsy Gleason score
≤6	25(50)	9(40.9)	16(57.1)	0.191
7	13(24)	5(22.7)	8(28.6)
8–10	12(26)	8(36.4)	4(14.3)
Pathological T stage
pT2	33(66)	12(54.5)	21(75)	0.292
pT3a	4(8)	2(9.1)	2(7.1)
pT3b	13(26)	8(36.4)	5(17.9)
Post-op Gleason score
≤6	22(44)	6(27.3)	16(57.1)	0.011
7	10(20)	3(13.6)	7(25)
8–10	18(36)	13(59.1)	5(17.9)
Seminal vesicle invasion
Yes	13(26)	8(36.4)	5(17.9)	0.139
No	37(74)	14(63.6)	23(82.1)
Lymphnode involvement
Yes	10(20)	7(31.8)	3(10.7)	0.064
No	40(80)	15(68.2)	25(89.3)
Surgical margin status
Yes	9(18)	7(31.8)	2(7.2)	0.024
No	41(82)	15(68.2)	26(92.9)